Ezio Bonvini
40Patents
10h-index
28Co-inventors
71Inventor score
Filing activity: Jul 11, 2006 → Aug 8, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8946387B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 79 | Active |
| US8193318B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 66 | Active |
| US9822181B2 | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof | Chemistry; Metallurgy | 57 | Active |
| US8187593B2 | FcγRIIB specific antibodies and methods of use thereof | Chemistry; Metallurgy | 52 | Active |
| US8663634B2 | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity | Chemistry; Metallurgy | 18 | Active |
| US8802093B2 | HER2/neu-specific antibodies and methods of using same | Chemistry; Metallurgy | 18 | Active |
| US10160806B2 | Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof | Chemistry; Metallurgy | 12 | Active |
| US9243069B2 | HER2/neu-specific antibodies and methods of using the same | Chemistry; Metallurgy | 11 | Active |
| US9376495B2 | Deimmunized serum-binding domains and their use in extending serum half-life | Chemistry; Metallurgy | 10 | Active |
| US10577422B2 | PD-1-binding molecules and methods of use thereof | Chemistry; Metallurgy | 10 | Active |
| US10647768B2 | Multi-chain polypeptide-containing tri-specific binding molecules | Emerging Cross-Sectional Technologies | 9 | Active |
| US10131713B2 | HER2/neu-specific antibodies and methods of using same | Chemistry; Metallurgy | 8 | Active |
| US10633440B2 | Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens | Emerging Cross-Sectional Technologies | 7 | Active |
| US9469692B2 | HER2/neu-specific antibodies and methods of using same | Chemistry; Metallurgy | 7 | Active |
| US9056906B2 | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity | Chemistry; Metallurgy | 4 | Active |
| US11028183B2 | HER2/neu-specific antibodies and methods of using same | Chemistry; Metallurgy | 2 | Active |
| US10787521B2 | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US10344092B2 | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US10954301B2 | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof | Chemistry; Metallurgy | 2 | Active |
| US11078279B2 | Combination therapy for the treatment of cancer | Chemistry; Metallurgy | 2 | Active |
| US10633443B2 | Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US9932400B2 | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US11072653B2 | LAG-3-binding molecules and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US11384149B2 | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US10961311B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.